NK-T cell activator (α-GalCer) accelerates immune and hematological reconstitution after murine allo-bone marrow transplantation.
- Author:
Jing-Hua LIU
1
;
Fan ZHOU
;
Li-Ping DOU
;
Yan-Qin LIU
;
Ji-Gang WANG
;
Ying BAI
;
Bu-Yun GUO
;
Li YU
Author Information
1. Department of Hematology, Shenyang Military Area General Hospital, Shenyang 110016, Liaoning Province, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Bone Marrow Transplantation;
immunology;
methods;
Chimera;
Female;
Galactosylceramides;
pharmacology;
Leukocyte Count;
Lymphocyte Activation;
drug effects;
Male;
Mice;
Mice, Inbred BALB C;
Mice, Inbred C57BL;
Natural Killer T-Cells;
drug effects;
immunology;
Postoperative Period
- From:
Journal of Experimental Hematology
2010;18(6):1542-1547
- CountryChina
- Language:Chinese
-
Abstract:
Immune reconstitution is crucially relevant for patients receiving hematopoietic stem cell transplantation (HSCT). This study was purposed to investigate the ability of α-GalCer (α-galactosylceramide), a well-known activator of natural killer T cells (NK-T), to enhance immune and hematological reconstitution. Lethally irradiated BALB/c mice were transplanted with allogeneic C57BL/6 bone marrow cells and splenocytes. α-GalCer was administered immediately after HSCT. After transplantation, the weight, activity, hairs, diarrhea and survival time of mice were observed daily; the blood routine test was performed once weekly; the donor chimeras, amount of mononuclear cells in spleen (MNC) and relative levels of CD3(+), CD4(+), CD8(+), B220(+), CD11c(+), CD40(+), CD86(+) and CD80(+) cells were detected by FACS on day 2, 7, 14, 27, 70 after transplantation. The results indicated that the MNC counts and relative levels of CD3(+) and CD4(+) in group treated with α-GalCer on day 2 after transplantation were higher than those in control group; at the same time, the detected donor chimeras were complete recipient type chimeras, then gradually transformed into donor type, on day 7 - 14 donor chimeras in α-GalCer group were enhanced significantly as compared with control group, on day 27 the chimeras in two groups were complete donor type chimeras thereafter to day 70, the MNC count and relative levels of CD3(+), CD4(+), CD8(+), B220(+), CD40(+), CD86(+) cells in α-GalCer group were obviously higher than those in control group, at the same time, the hematopoietic reconstitution in α-GalCer group was accelerated as compared with control group. It is concluded that the α-GalCer administration after allogeneic bone marrow transplantations accelerates immune and hematological reconstitution.
